Healthcare shares are flat in pre-market trade. In earnings
news, Endo Health Solutions (
) reported Q2 earnings of $1.42 per share, ex one-time items,
versus the Capital IQ consensus of $1.15. Revenues were $766.6
million, versus the analyst estimate of $721.61 million.
The company now expects FY13 EPS of $4.25 - $4.55, ex
non-recurring items, down from the previous guidance range of $4.40
- $4.70 and compared with the Street view of $4.33. Revenues are
now expected to be $2.7 billion - 2.8 billion, down from the prior
guidance of $2.80 billion - $2.95 billion. Analysts are looking for
revenues of $2.75 billion.
ENDP shares closed at $38.71 with a 52-week range of $25.00 -
And, Regeneron Pharmaceuticals Inc. (
) reported Q2 2013 non-GAAP net income of $198 million, or $1.73
per diluted share, on revenues of $458 million. Analysts expected
revenues of $473.2 million and GAAP earnings per share of $0.88, if
In the same period last year, non-GAAP net income was $102
million, or $0.90 per diluted share, on revenues of $304 million.
REGN is down 3.5% at $261.50.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.